Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Pediatric Moderately to Severely Active Ulcerative Colitis (Japan, Phase 3)
jRCT2031230330Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of mirikizumab in autoimmune colitis (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants with modified Mayo score (MMS) Clinical Remission at Week 52 among the Week 12 Clinical Responders. Started Nov 2023; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031230330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230330.